Inactive Instrument

Heska Corporation

HSKA

US42805E3062

Medical Equipment, Supplies & Distribution

Heska Corporation Provides Earnings Guidance for the Full Year 2022

February 28, 2022 at 08:00 am EST

Heska Corporation provided earnings guidance for the full year 2022. For the year, the company expected Consolidated Revenue in the range of $287 million to $297 million.

Latest news about Heska Corporation

Veterinary Pharmaceutical Solutions acquired Heska Corporation from Mars, Incorporated.	Dec. 28	CI
Heska Corporation(NasdaqCM:HSKA) dropped from S&P 600	23-06-14	CI
Heska Corporation(NasdaqCM:HSKA) dropped from S&P Composite 1500	23-06-14	CI
Heska Corporation(NasdaqCM:HSKA) dropped from S&P Healthcare Equipment Select Industry Index	23-06-14	CI
Heska Corporation(NasdaqCM:HSKA) dropped from S&P TMI Index	23-06-14	CI
Heska Corporation(NasdaqCM:HSKA) dropped from S&P 1000	23-06-14	CI
Heska Corporation(NasdaqCM:HSKA) dropped from S&P Global BMI Index	23-06-14	CI
Heska Corporation(NasdaqCM:HSKA) dropped from S&P 600 Health Care	23-06-14	CI
Heska Corporation Announces Board Changes	23-06-13	CI
Heska Corporation(NasdaqCM:HSKA) dropped from NASDAQ Composite Index	23-06-13	CI
Antech Diagnostics, Inc. completed the acquisition of Heska Corporation from BlackRock, Inc., The Vanguard Group, Inc. and others.	23-06-12	CI
EXp World to Replace Heska, Privia Health to Replace Ruth's Hospitality on S&P SmallCap 600; Shares Rise	23-06-08	MT
EXp World to Replace Heska, Privia Health to Replace Ruth's Hospitality on S&P SmallCap 600	23-06-08	MT
Transcript : Heska Corporation - Shareholder/Analyst Call	23-06-07
Earnings Flash (HSKA) HESKA CORPORATION Posts Q1 Revenue $62.4M	23-05-05	MT
Earnings Flash (HSKA) HESKA CORPORATION Reports Q1 EPS $0.17	23-05-05	MT
Heska Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Transcript : Heska Corporation - Shareholder/Analyst Call	23-05-03
Heska Agrees to Buyout Deal With Dog Food Pedigree Maker Mars	23-04-03	MT
Alliance Global Downgrades Heska to Neutral From Buy, Cuts Price Target to $120 From $129	23-04-03	MT
Morgan Stanley Upgrades Heska to Equalweight From Underweight, Raises Price Target to $120 From $58	23-04-03	MT
Heska Agrees to be Acquired by Mars; Shares Rise	23-04-03	MT
Mars to buy veterinary diagnostics firm Heska for $1.3 bln	23-04-03	RE
Sector Update: Healthcare Stocks Lose Ground in Late Trading	23-02-28	MT
Sector Update: Health Care	23-02-28	MT

Heska Corporation sells, manufactures, markets and supports diagnostic and specialty products and solutions for veterinary practitioners. The Company's portfolio includes point-of-care (POC) diagnostic laboratory instruments and consumables, POC digital imaging diagnostic products, local and cloud-based data services, practice information management software (PIMS) and related software and support, reference laboratory testing, allergy testing and immunotherapy, heartworm preventive products, and vaccines. The Company has two segments. The North America segment consists of the United States, Canada and Mexico. The segment also includes the contract manufacturing of vaccines and pharmaceutical products and a small veterinary laboratory. The International segment consists of geographies outside of North America, primarily its operations in Germany, Italy, Spain, France, Switzerland, Australia and Malaysia. The segment includes its PIMS business and veterinary laboratories.

Sector

Medical Equipment, Supplies & Distribution

More about the company